Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

News Focus

Lipari Mining (N.LML) Announces Q1-2025 Production and Sales Results (click to learn more)

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Nanomix Corp NNMX

Healthcare Medical Devices

Nanomix Corporation is engaged in development of mobile point-of-care diagnostics. The Company operates through its Nanomix eLab System platform and assays that provide quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The platform is designed to provide rapid test results in a handheld device at the first point of patient... see more

Add To Watchlist

Recent & Breaking News (OTCPK:NNMX)

Boston Therapeutics Signs Agreement With Patheon to Manufacture Pharmaceutical-Grade BTI-320 Tablets

Marketwired May 6, 2014

Boston Therapeutics to Present Late-Breaking Poster on Mechanism of Action for BTI-320 at AACE Annual Congress in Las Vegas on May 14-18

Marketwired April 29, 2014

Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Boston Therapeutics, Inc.

Marketwired March 27, 2014

Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Boston Therapeutics, Inc.

Marketwired March 27, 2014

SeeThruEquity Issues Quarterly Update on Boston Therapeutics

Business Wire March 18, 2014

Boston Therapeutics Reports Corporate Update and Financial Results for the Fourth Quarter and Year Ended December 31, 2013

Marketwired March 17, 2014

Boston Therapeutics to Initiate a Phase II Clinical Study of BTI-320 in U.S.

Marketwired March 4, 2014

Boston Therapeutics Appoints Larry K. Ellingson, Former Chair of the American Diabetes Association, as Chair of Its Scientific Advisory Board

Marketwired February 25, 2014

Boston Therapeutics Signs Agreement to Market SugarDown(R) in the U.S.

Marketwired February 11, 2014

Boston Therapeutics Appoints Three to Management Positions

Marketwired December 10, 2013

Boston Therapeutics, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com

PR Newswire December 6, 2013

Boston Therapeutics Appoints Conroy Chi-Heng Cheng and S. Colin Neill to Board of Directors

Marketwired December 4, 2013

Boston Therapeutics Presents at the Elsevier Therapeutic Area Partnerships 2013 Conference in Boston on November 19

Marketwired November 18, 2013

Boston Therapeutics Exhibits at Obesity Week 2013 Conference

Marketwired November 14, 2013

Boston Therapeutics Reports Corporate Update and Financial Results for the Third Quarter and Nine Months Ended September 30, 2013

Marketwired November 13, 2013

Boston Therapeutics Enrolls Patients With Type 2 Diabetes in a Phase IIb Clinical Trial With PAZ320

Marketwired November 12, 2013

Boston Therapeutics to Present at the Livingston Securities Advanced and Nano Life Sciences Summit

Marketwired October 16, 2013

Boston Therapeutics Initiates Research Study on PAZ320 at University of Minnesota

Marketwired October 15, 2013

Systemic Versus Non-Systemic Diabetes Drugs

ACCESS Newswire October 7, 2013

Boston Therapeutics Closes $5.3 Million in Private Placement of Common Stock and Warrants

Marketwired October 3, 2013